Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial
JD Hainsworth, DR Spigel, JA Sosman… - Clinical genitourinary …, 2007 - Elsevier
Purpose The aim of this study was to evaluate the efficacy and toxicity of imatinib, a platelet-
derived growth factor-β receptor antagonist, when added to the combination
bevacizumab/erlotinib in the treatment of patients with advanced clear cell renal carcinoma.
Patients and Methods Ninety-four patients with metastatic clear cell renal carcinoma were
treated with bevacizumab 10 mg/kg intravenously every 2 weeks, erlotinib 150 mg orally
daily, and imatinib 400 mg orally daily. Patients were reevaluated after 8 weeks of treatment; …
derived growth factor-β receptor antagonist, when added to the combination
bevacizumab/erlotinib in the treatment of patients with advanced clear cell renal carcinoma.
Patients and Methods Ninety-four patients with metastatic clear cell renal carcinoma were
treated with bevacizumab 10 mg/kg intravenously every 2 weeks, erlotinib 150 mg orally
daily, and imatinib 400 mg orally daily. Patients were reevaluated after 8 weeks of treatment; …